# IICT transfers diabetic wound treatment to Viridis Biopharma 2026-08-12T22:35:13+00:00 | Governance | Indian Opinion Desk Corroboration: 1 independent outlet The Indian Institute of Chemical Technology (IICT) has transferred a phytopharmaceutical technology for treating diabetic foot ulcers to Viridis Biopharma Pvt Ltd. The technology, developed from the herb 'Gymnema sylvestre' (Gurmar), is IND-ready, meaning it has completed preclinical testing. Viridis will now handle regulatory submissions to India's CDSCO and the US FDA, aiming to move the formulation into clinical evaluation. The research, supported under the CSIR Phytopharmaceutical Mission Phase-III, included botanical standardisation, pharmacological studies, and safety evaluations. IICT director Srinivasa Reddy said the transfer reflects efforts to move research towards healthcare. Viridis director Anslem de Souza stated the treatment fulfils a gap in current wound management. The programme also has potential for other chronic wounds and inflammatory skin disorders. ## Coverage - timesofindia.indiatimes.com Tags: clinical trials, CSIR, diabetic foot ulcer, Gymnema sylvestre, IICT, phytopharmaceutical Canonical: https://indianopinion.org/iict-transfers-diabetic-wound-treatment-to-viridis-biopharma/ License: Summary and commentary (c) Indian Opinion, reusable with attribution. Facts belong to the linked sources. Cite: https://indianopinion.org/iict-transfers-diabetic-wound-treatment-to-viridis-biopharma/#story-in-brief Review state: restored archive article, accurate at time of publication, not offered to search indexes.